Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedMar 30, 2026
DataAggregated Company Financials
Companies147
  • 7D3.1%
  • 3M-7.3%
  • 1Y-4.9%
  • YTD-5.7%

Over the last 7 days, the Healthcare industry has risen 3.1%, driven by gains from Swedish Orphan Biovitrum of 7.1%. In the past year, the industry is down 4.9%. Earnings are forecast to grow by 25% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 30 Mar 2026SEK 547.9bSEK 228.9b-SEK 2,733,778,471.3429.3x-200.4x2.4x
Wed, 25 Feb 2026SEK 559.7bSEK 229.3b-SEK 1,651,995,542.8531.5x-338.8x2.4x
Fri, 23 Jan 2026SEK 597.9bSEK 229.9bSEK 3.7b42.1x163.4x2.6x
Sun, 21 Dec 2025SEK 580.7bSEK 230.6bSEK 3.7b41.6x159.1x2.5x
Tue, 18 Nov 2025SEK 596.4bSEK 230.4bSEK 2.9b44.2x203.4x2.6x
Thu, 16 Oct 2025SEK 595.6bSEK 227.2bSEK 6.7b42.1x89.2x2.6x
Sat, 13 Sep 2025SEK 613.4bSEK 227.0bSEK 6.6b45.5x93x2.7x
Mon, 11 Aug 2025SEK 605.4bSEK 226.8bSEK 6.8b47.1x89x2.7x
Wed, 09 Jul 2025SEK 631.4bSEK 226.8bSEK 6.0b44.9x104.9x2.8x
Fri, 06 Jun 2025SEK 630.5bSEK 226.4bSEK 5.9b43.8x107.4x2.8x
Sun, 04 May 2025SEK 599.5bSEK 223.6bSEK 4.9b36.9x122x2.7x
Tue, 01 Apr 2025SEK 560.9bSEK 221.0bSEK 5.4b35.8x103.8x2.5x
Thu, 27 Feb 2025SEK 587.8bSEK 206.1bSEK 4.4b36.5x133.4x2.9x
Sat, 25 Jan 2025SEK 583.0bSEK 202.6b-SEK 2,674,645,991.0140.6x-218x2.9x
Mon, 23 Dec 2024SEK 575.6bSEK 202.7b-SEK 2,503,527,932.1738.8x-229.9x2.8x
Wed, 20 Nov 2024SEK 502.8bSEK 199.9b-SEK 2,728,483,299.5237.9x-184.3x2.5x
Fri, 18 Oct 2024SEK 595.1bSEK 198.6b-SEK 2,314,740,798.5340x-257.1x3x
Sun, 15 Sep 2024SEK 622.6bSEK 200.0b-SEK 2,795,377,192.9841.1x-222.7x3.1x
Tue, 13 Aug 2024SEK 572.9bSEK 199.5b-SEK 2,609,110,124.0441.3x-219.6x2.9x
Thu, 11 Jul 2024SEK 571.0bSEK 195.8b-SEK 3,206,775,485.6038.5x-178.1x2.9x
Sat, 08 Jun 2024SEK 563.8bSEK 195.9b-SEK 3,096,791,185.5538.2x-182.1x2.9x
Mon, 06 May 2024SEK 537.6bSEK 196.5b-SEK 3,171,705,888.4334.8x-169.5x2.7x
Wed, 03 Apr 2024SEK 520.4bSEK 193.0b-SEK 3,321,080,753.9446.2x-156.7x2.7x
Fri, 01 Mar 2024SEK 503.6bSEK 191.9b-SEK 3,900,710,113.9148.2x-129.1x2.6x
Sun, 28 Jan 2024SEK 551.4bSEK 191.7b-SEK 915,162,632.0049.4x-602.6x2.9x
Tue, 26 Dec 2023SEK 534.3bSEK 191.0b-SEK 960,233,351.0047.8x-556.5x2.8x
Thu, 23 Nov 2023SEK 494.6bSEK 190.0b-SEK 1,226,498,819.0049.9x-403.3x2.6x
Sat, 21 Oct 2023SEK 421.9bSEK 185.4b-SEK 1,948,225,629.0031.5x-216.6x2.3x
Mon, 18 Sep 2023SEK 453.7bSEK 185.7b-SEK 1,988,033,258.0036.2x-228.2x2.4x
Wed, 16 Aug 2023SEK 469.0bSEK 184.3b-SEK 1,029,422,273.0041.8x-455.6x2.5x
Fri, 14 Jul 2023SEK 470.8bSEK 178.8b-SEK 741,943,195.0044.7x-634.6x2.6x
Sun, 11 Jun 2023SEK 511.5bSEK 179.0b-SEK 714,102,762.0040.9x-716.3x2.9x
Tue, 09 May 2023SEK 527.1bSEK 176.7b-SEK 700,463,228.0042.7x-752.5x3x
Thu, 06 Apr 2023SEK 497.6bSEK 172.1b-SEK 1,186,851,890.0034.6x-419.3x2.9x
Price to Earnings Ratio

-419.3x


Total Market Cap: SEK 497.6bTotal Earnings: -SEK 1,186,851,890.00Total Revenue: SEK 172.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -164.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 10.0% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market0.097%
Healthcare3.06%
Biotech5.93%
Medical Equipment2.60%
Healthcare Services1.77%
Pharma0.43%
Healthtech-1.17%
Life Sciences-1.35%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 116x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 383.606.6%
+SEK 8.2b		33.5%PE277.4x
ASKER Asker Healthcare GroupSEK 67.507.6%
+SEK 1.8b		-16.1%PE56.2x
GETI B GetingeSEK 187.352.9%
+SEK 1.4b		-13.2%PE22.6x
VIMIAN Vimian GroupSEK 27.6010.2%
+SEK 1.4b		-35.1%PE42.8x
XVIVO Xvivo PerfusionSEK 219.2015.2%
+SEK 913.5m		-22.1%PE274.4x

Latest News

SOBI
SEK 383.60
Swedish Orphan Biovitrum
7D
6.6%
1Y
33.5%
DMYD B
SEK 1.43
Diamyd Medical
7D
-91.2%
1Y
-82.3%
GETI B
SEK 187.35
Getinge
7D
2.9%
1Y
-13.2%

Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next

Mar 29
Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
MAGLE
SEK 4.02
Magle Chemoswed Holding
7D
-45.7%
1Y
-86.3%
ASKER
SEK 67.50
Asker Healthcare Group
7D
7.6%
1Y
-16.1%
SECARE
SEK 23.60
Swedencare
7D
-1.0%
1Y
-37.9%
FLUO
SEK 37.40
FluoGuide
7D
-8.6%
1Y
2.0%
CURAS
DKK 14.05
Curasight
7D
-3.8%
1Y
90.4%
XVIVO
SEK 219.20
Xvivo Perfusion
7D
15.2%
1Y
-22.1%

XVIVO: Higher Margins And Discount Assumptions Will Support Future Upside Potential

Analysts have modestly reduced their price target for Xvivo Perfusion to SEK245. This reflects slightly higher discount rate assumptions alongside small adjustments to revenue growth, profit margin, and future P/E expectations.
BONEX
SEK 187.50
Bonesupport Holding
7D
5.0%
1Y
-36.2%

BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential

Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
VIMIAN
SEK 27.60
Vimian Group
7D
10.2%
1Y
-35.1%
SECT B
SEK 223.40
Sectra
7D
1.5%
1Y
-6.7%

SECT B: Cloud Deals And Rating Upgrades Will Shape Balanced Return Profile

Sectra's analyst price target has been revised from SEK 220 to about SEK 228. Analysts have issued refreshed Buy ratings and higher targets in the SEK 210 to SEK 250 range that reflect updated views on growth, profitability and future P/E assumptions.
CAMX
SEK 461.40
Camurus
7D
2.8%
1Y
-19.0%

CAMX: 2026 Guidance And US FDA Review Will Drive Future Upside

Analysts have kept their SEK 930 price target for Camurus unchanged, citing only minor adjustments in their assumptions for revenue growth, profit margin and future P/E as the main reasons for maintaining this level. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).
SUS
SEK 29.44
Surgical Science Sweden
7D
-3.9%
1Y
-76.0%

SUS: Organic Expansion Will Support Sector Leadership As Profitability Assumptions Are Refined

Analysts have trimmed their fair value estimate for Surgical Science Sweden from SEK 61 to SEK 57.6, reflecting tweaks to assumptions around the discount rate, revenue growth, profit margins and expected future P/E levels. Valuation Changes Fair Value: Reduced from SEK 61 to SEK 57.6, a trim of about 6% in the modelled estimate.
SANION
SEK 15.06
Saniona
7D
-4.6%
1Y
156.6%
CINPHA
SEK 17.06
Cinclus Pharma Holding
7D
-4.7%
1Y
43.4%